Mitsuoka Keisuke, Miyoshi Sosuke, Kato Yukio, Murakami Yoshihiro, Utsumi Rie, Kubo Yoshiyuki, Noda Akihiro, Nakamura Yukio, Nishimura Shintaro, Tsuji Akira
Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa, Ishikawa, Japan.
J Nucl Med. 2008 Apr;49(4):615-22. doi: 10.2967/jnumed.107.048231. Epub 2008 Mar 14.
H+/peptide transporter, PEPT1, is functionally expressed in some human cancer cell lines and might be a candidate molecular target for detection of cancers in vivo using PET. The aim of the present study was to establish a novel tumor-imaging technology using a PET tracer targeted to H+/peptide transporter(s). We also compared the tracer with 18F-FDG, focusing on the specificity of their accumulation between tumor and inflammatory tissues.
A dipeptide PET tracer, 11C-glycylsarcosine (11C-Gly-Sar), was injected intravenously into athymic mice transplanted with human pancreatic, prostate, and gastric cancer cells. The distribution patterns of 11C-Gly-Sar and 18F-FDG in the tumor-bearing mice, and in mice with inflammatory tissue, were assessed by imaging with a positron planar imaging system (PPIS). Tissue distributions of tracer radioactivity were also measured. The expression levels of PEPT1 and PEPT2 (PEPTs) proteins in tumor xenografts and inflammatory tissue were examined by immunohistochemical analysis. The messenger RNA expression levels of PEPTs in 58 available cancer cell lines were quantified by means of real-time polymerase chain reaction.
All 3 tumor xenografts were well visualized with the PPIS after injection of 11C-Gly-Sar. Expression of PEPTs in those xenografts was confirmed by immunohistochemical analysis. Tumor-to-blood concentration ratios of 11C-Gly-Sar increased in a time-dependent manner and were much higher than unity. Most of the radioactivity found in the tumor tissue was recovered as the intact tracer. These results indicated that 11C-Gly-Sar was taken up by the PEPTs in tumor xenografts. It is noteworthy that 11C-Gly-Sar was minimally present in inflammatory tissues that expressed no PEPT1 or PEPT2 protein, whereas 18F-FDG was highly accumulated, with the values of the selectivity index being >25.1 and 0.72 for 11C-Gly-Sar and 18F-FDG, respectively. The mRNAs of PEPT1 and PEPT2 were expressed in 27.6% and 93.1%, respectively, of the cancer cell lines examined in the present study.
The present study indicates that 11C-Gly-Sar is a promising tumor-imaging agent and is superior to 18F-FDG for distinguishing between tumors and inflammatory tissue. Because PEPTs were ubiquitously expressed in various types of tumor cells examined, 11C-Gly-Sar could be useful for the detection of many types of cancers.
氢离子/肽转运体PEPT1在一些人类癌细胞系中具有功能表达,可能是利用正电子发射断层显像(PET)在体内检测癌症的候选分子靶点。本研究的目的是建立一种使用靶向氢离子/肽转运体的PET示踪剂的新型肿瘤成像技术。我们还将该示踪剂与18F-氟代脱氧葡萄糖(18F-FDG)进行了比较,重点关注它们在肿瘤组织和炎症组织中的聚集特异性。
将二肽PET示踪剂11C-甘氨酰肌氨酸(11C-Gly-Sar)静脉注射到移植了人胰腺癌细胞、前列腺癌细胞和胃癌细胞的无胸腺小鼠体内。通过正电子平面成像系统(PPIS)成像评估11C-Gly-Sar和18F-FDG在荷瘤小鼠以及有炎症组织的小鼠体内的分布模式。还测量了示踪剂放射性在组织中的分布情况。通过免疫组织化学分析检测肿瘤异种移植物和炎症组织中PEPT1和PEPT2(统称为PEPTs)蛋白的表达水平。利用实时聚合酶链反应对本研究中58种可用癌细胞系中PEPTs的信使核糖核酸表达水平进行定量。
注射11C-Gly-Sar后,所有3种肿瘤异种移植物均能通过PPIS清晰显像。免疫组织化学分析证实了这些异种移植物中PEPTs的表达。11C-Gly-Sar的肿瘤与血液浓度比呈时间依赖性增加,且远高于1。在肿瘤组织中发现的大部分放射性以完整示踪剂的形式回收。这些结果表明11C-Gly-Sar被肿瘤异种移植物中的PEPTs摄取。值得注意的是,11C-Gly-Sar在不表达PEPT1或PEPT2蛋白的炎症组织中含量极少,而18F-FDG高度聚集,11C-Gly-Sar和18F-FDG的选择性指数值分别>25.1和0.72。在本研究检测的癌细胞系中,PEPT1和PEPT2的信使核糖核酸分别在27.6%和93.1%的细胞系中表达。
本研究表明11C-Gly-Sar是一种有前景的肿瘤成像剂,在区分肿瘤组织和炎症组织方面优于18F-FDG。由于PEPTs在检测的各种类型肿瘤细胞中普遍表达,11C-Gly-Sar可能有助于多种类型癌症的检测。